/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

Galmed Pharmaceuticals Ltd

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$1.04 0.1159(11.59%) GLMD at 04 Dec 2025 04:33 PM Biotechnology
Lowest Today 0.9601
Highest Today 1.08
Today’s Open 0.9601
Prev. Close 0.9589
52 Week High 3.61
52 Week Low 0.74
Day’s Range: Low 0.9601 High 1.08
52-Week Range: Low 0.74 High 3.61
1 day return -
1 Week return +16.75
1 month return -10.0
3 month return -16.92
6 month return -27.51
1 year return -61.29
3 year return -75.42
5 year return -98.02
10 year return -

Institutional Holdings

Morgan Stanley - Brokerage Accounts 0.61

Schonfeld Strategic Advisors LLC 0.42

CAMBRIDGE Invest RESEARCH ADVISORS, INC. 0.18

UBS Group AG 0.13

SBI Securities Co Ltd 0.04

Macquarie Healthcare I 0.03

Uma Financial Services Inc 0.00

Federation des caisses Desjardins du Quebec 0.00

TSFG, LLC 0.00

Wells Fargo & Co 0.00

Advisor Group Holdings, Inc. 0.00

Dogwood Wealth Management LLC 0.00

Hanson Mcclain Inc 0.00

TD Waterhouse Canada Inc 0.00

Tower Research Capital LLC 0.00

TWO SIGMA SECURITIES, LLC 0.00

Virtu Financial LLC 0.00

ZRC WEALTH MANAGEMENT, LLC 0.00

Market Status

Strong Buy: 0

Buy: 0

Hold: 1

Sell: 0

Strong Sell: 0

Fundamentals

Market Cap 5.25 M

PB Ratio 0.2601

PE Ratio 0.0

Enterprise Value -7.26 M

Total Assets 18.50 M

Volume 258658

Company Financials

Annual Revenue FY23:0 0.0M, FY22:0 0.0M, FY21:0 0.0M, FY20:0 0.0M, FY19:0 0.0M

Annual Profit FY23:null 0.0M, FY22:null 0.0M, FY21:null 0.0M, FY20:null 0.0M, FY19:null 0.0M

Annual Net worth FY23:-7535000 -7.5M, FY22:-18571000 -18.6M, FY21:-31948000 -31.9M, FY20:-27610000 -27.6M, FY19:-18541000 -18.5M

Quarterly Revenue Q2/2025:0 0.0M, Q1/2025:0 0.0M, Q3/2024:0 0.0M, Q2/2024:0 0.0M, Q1/2024:0 0.0M

Quarterly Profit Q2/2025:null 0.0M, Q1/2025:null 0.0M, Q3/2024:null 0.0M, Q2/2024:-74000 -0.1M, Q1/2024:-9000 -0.0M

Quarterly Net worth Q2/2025:-2495000 -2.5M, Q1/2025:-1104000 -1.1M, Q3/2024:-1914000 -1.9M, Q2/2024:-1119000 -1.1M, Q1/2024:-1275000 -1.3M

Fund house & investment objective

Company Information Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. Further, the company develops MyBiotics which is in pre-clinical trials for NASH and fibrosis. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Ramat Gan, Israel.

Organisation Biotechnology

Employees 3

Industry Biotechnology

CEO Mr. Allen Baharaff

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow